GLUE Monte Rosa Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GLUE

Price (delayed)

$5.65

Market cap

$283.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.63

Enterprise value

$201.31M

Highlights
The debt has declined by 2% year-on-year
Monte Rosa Therapeutics's EPS has decreased by 14% YoY but it has increased by 2.2% from the previous quarter
The quick ratio has dropped by 53% year-on-year and by 37% since the previous quarter
The equity has declined by 34% year-on-year and by 2.9% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of GLUE
Market
Shares outstanding
50.15M
Market cap
$283.37M
Enterprise value
$201.31M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.58
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$135.01M
EBITDA
-$128.79M
Free cash flow
-$62.78M
Per share
EPS
-$2.63
Free cash flow per share
-$1.22
Book value per share
$3.58
Revenue per share
$0
TBVPS
$5.91
Balance sheet
Total assets
$303.76M
Total liabilities
$124.51M
Debt
$46.04M
Equity
$179.25M
Working capital
$189.62M
Liquidity
Debt to equity
0.26
Current ratio
5.07
Quick ratio
5
Net debt/EBITDA
0.64
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-47.3%
Return on equity
-65.9%
Return on invested capital
-57.9%
Return on capital employed
-52.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GLUE stock price

How has the Monte Rosa Therapeutics stock price performed over time
Intraday
0.89%
1 week
6%
1 month
-18.47%
1 year
15.07%
YTD
0%
QTD
-19.86%

Financial performance

How have Monte Rosa Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$143.31M
Net income
-$135.35M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 28% year-on-year
The net income has contracted by 25% YoY

Growth

What is Monte Rosa Therapeutics's growth rate over time

Valuation

What is Monte Rosa Therapeutics stock price valuation
P/E
N/A
P/B
1.58
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Monte Rosa Therapeutics's EPS has decreased by 14% YoY but it has increased by 2.2% from the previous quarter
The equity has declined by 34% year-on-year and by 2.9% since the previous quarter
GLUE's P/B is 5% above its last 4 quarters average of 1.5

Efficiency

How efficient is Monte Rosa Therapeutics business performance
GLUE's ROE has dropped by 81% year-on-year and by 13% since the previous quarter
Monte Rosa Therapeutics's ROA has plunged by 54% YoY and by 5% from the previous quarter
The ROIC has contracted by 42% YoY and by 16% from the previous quarter

Dividends

What is GLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GLUE.

Financial health

How did Monte Rosa Therapeutics financials performed over time
GLUE's total assets is 144% greater than its total liabilities
The total liabilities has surged by 84% since the previous quarter and by 75% year-on-year
The company's current ratio has shrunk by 53% YoY and by 37% QoQ
The debt is 74% smaller than the equity
The debt to equity has soared by 53% YoY and by 4% from the previous quarter
The equity has declined by 34% year-on-year and by 2.9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.